U.S. Markets close in 2 hrs 49 mins

  • S&P 500

    4,140.65
    -39.11 (-0.94%)
     

  • Dow 30

    33,897.01
    -156.93 (-0.46%)
     

  • Nasdaq

    12,057.33
    -143.49 (-1.18%)
     

  • Russell 2000

    2,001.99
    +0.77 (+0.04%)
     

  • Crude Oil

    73.76
    -2.12 (-2.79%)
     

  • Gold

    1,876.10
    -54.70 (-2.83%)
     

  • Silver

    22.36
    -1.25 (-5.31%)
     

  • EUR/USD

    1.0817
    -0.0094 (-0.8653%)
     

  • 10-Yr Bond

    3.5150
    +0.1190 (+3.50%)
     

  • Vix

    18.43
    -0.30 (-1.60%)
     

  • GBP/USD

    1.2067
    -0.0162 (-1.3261%)
     

  • USD/JPY

    131.0270
    +2.4230 (+1.8841%)
     

  • BTC-USD

    23,496.04
    -438.31 (-1.83%)
     

  • CMC Crypto 200

    538.04
    +1.18 (+0.22%)
     

  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     

  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis

Vandana Singh
·1 min read

  • NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children.

  • The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate NV-CoV-2 to combat COVID-19.

  • NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, although the timelines are outside the company's control.

  • Related: EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate.

  • The company believes it can successfully develop a drug candidate against hAd41-F relatively quickly if one or more of its existing pipeline candidates or other nanoviricide candidates in its drug candidate library is effective.

  • NanoViricides is developing an antiviral assay for testing these drug candidates against hAd41-F infection in cell cultures in its virology facility.

  • It is thought that a combination of prior SARS-CoV-2 exposure or infection, along with current hAd41-F infection, may be responsible for hepatitis cases. However, no definitive cause of this severe hepatitis syndrome has been established.

  • As reported by NBC News online, the number of cases worldwide has risen to 450 as of May 15.

  • Related: Six US States Probing Mysterious Liver Inflammation In Kids: Bloomberg.

  • Price Action: NNVC shares are up 16.10% at $1.50 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories